At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Metformindrug
Likely dose
Metformin 1500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation
In Brief
A Phase 2 clinical trial evaluating Metformin for Breast Cancer. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The purpose of this pilot study is to use a pre surgical intervention model to evaluate the biologic effects of metformin in women with newly diagnosed early invasive breast cancer. Metformin is a drug commonly used to treat patients with diabetes. This model will be used to evaluate the effects of metformin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBreast Cancer Research Foundation
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartOct 2009
Primary CompletionMay 2012
Study CompletionJan 2017
TodayJul 2026
First PostedJun 30, 2009
Enrollment StartOct 16, 2009
Primary CompletionMay 10, 2012
Study CompletionJan 9, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 17.0 years ago
Interventions
Metformindrug
1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery